3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
9
Other hematologic neoplasm
8
Lymphoid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
25
Myelodysplastic Syndromes
17
Lymphoma, Non-Hodgkin
16
Lymphoma
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Lymphoma, Large B-Cell, Diffuse
14
Lymphoma, T-Cell, Peripheral
13
Multiple Myeloma
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Recurrence
10
Leukemia
10
Hodgkin Disease
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell
7
Lymphoma, Follicular
7
Hematologic Neoplasms
7
Lymphoma, B-Cell, Marginal Zone
6
Leukemia, Biphenotypic, Acute
6
Lymphoma, Extranodal NK-T-Cell
5
Leukemia, Myelomonocytic, Chronic
5
Primary Myelofibrosis
4
Myeloproliferative Disorders
4
Lymphoma, Mantle-Cell
4
Lymphoma, B-Cell
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Immunoblastic Lymphadenopathy
4
Prostatic Neoplasms
3
Neoplasms, Plasma Cell
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Large-Cell, Anaplastic
3
Interventions
Cyclophosphamide
38
fludarabine phosphate
34
Peripheral Blood Stem Cell Transplantation
28
Busulfan
26
Tacrolimus
22
Antilymphocyte Serum
22
Mycophenolic Acid
21
Filgrastim
20
Cyclosporine
20
Radiotherapy
17
Methotrexate
16
Melphalan
14
Whole-Body Irradiation
12
Etoposide
12
Methylprednisolone
11
Cord Blood Stem Cell Transplantation
11
Cytarabine
8
Sirolimus
7
Alemtuzumab
7
Psychiatric Rehabilitation
6
Flow Cytometry
6
Cyclosporins
6
Thiotepa
5
Rituximab
5
Polymerase Chain Reaction
4
Early Intervention, Educational
4
sargramostim
3
Immunologic Techniques
3
Immunoenzyme Techniques
3
Granulocyte Colony-Stimulating Factor
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic-Myeloproliferative Diseases
×
Azacitidine
×
Lymphoid
×
Clear all
NCT05609942
2025-04-10
AZURE
Blueprint Medicines Corporation
Phase 1
Terminated
9 enrolled